Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552593347> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2552593347 abstract "Abstract Autologous peripheral blood stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma (MM). High-dose melphalan is considered the current standard of care among the preparative regimens used in ASCT for MM patients. We report the results of ASCT in 79 consecutive MM patients using a conditioning regimen with busulfan and cyclophosphamide (Bu/Cy), given as single ASCT and without maintenance therapy. Peripheral blood stem cells were mobilized with cyclophosphamide 5,000 mg/m2 IV + etoposide 1,000 mg/m2 IV, followed by granulocyte colony stimulating factor (G-CSF) 5 mg/Kg/day until the end of stem cell collection. A median of 41.1 × 106 CD34+ cells/Kg (range, 2.1–139.7 × 106) of ideal body weight were mobilized. The conditioning regimen consisted of busulfan 1 mg/Kg PO or 0.8 mg/Kg IV every 6 hours x 16 doses (days -7 to -3), and cyclophosphamide 60 mg/Kg/day IV for 2 days (days -3 to -2). Patients achieved neutrophil engraftment (absolute neutrophil count >500/μL) at a median of +13 days (range, +6 to +21 days), and platelet engraftment (platelets >20,000/μL unsupported by transfusion) at a median of 14 days (range, +11 to +24). Using a transfusion threshold of hemoglobin <8.0 g/dL and platelets <10,000/μL, patients required a median of 2 units of RBC transfusions (range, 0–8), and 1 platelet transfusion (range, 0–15) until hematologic engraftment. Forty-eight and 20 patients reached PR and CR, respectively, for an overall RR of 86%. At a median followup of 41 months (range 2–132 months), the estimated median overall survival (OS) and progression-free survival (PFS) were 45 months [95% confidence interval (CI) = 38–92] and 20 months (95% CI = 15–25), respectively. Veno-occlusive disease developed in 4 pts, and it was lethal in 1 of them. The Bu/Cy regimen was overall well tolerated, and transplant-related mortality was 4%. No statistically significant difference in terms of OS and EFS were observed between the group of patients receiving oral (n=13) vs IV busulfan (n=66). OS was not statistically different between the group receiving ASCT in first remission (n=62) and the group receiving ASCT as salvage therapy, i.e., upon MM progression (n=17), either calculating OS from the day of ASCT or from the day of MM diagnosis. We conclude that our reported clinical outcomes of the Bu/Cy regimen are equivalent to those obtained in historical controls with high-dose melphalan followed by a single ASCT. Thus, given the equivalent effectiveness but greater complexity of administration of the Bu/Cy regimen compared with that of single agent melphalan, we believe the latter should remain the agent of choice for ASCT in MM." @default.
- W2552593347 created "2016-11-30" @default.
- W2552593347 creator A5003442418 @default.
- W2552593347 creator A5004302802 @default.
- W2552593347 creator A5006190727 @default.
- W2552593347 creator A5015542767 @default.
- W2552593347 creator A5018176156 @default.
- W2552593347 creator A5059838967 @default.
- W2552593347 creator A5076439728 @default.
- W2552593347 date "2008-11-16" @default.
- W2552593347 modified "2023-09-26" @default.
- W2552593347 title "Single Autologous Stem Cell Transplant Using Busulfan and Cyclophosphamide as Conditioning Regimen in Patients with Multiple Myeloma" @default.
- W2552593347 doi "https://doi.org/10.1182/blood.v112.11.4436.4436" @default.
- W2552593347 hasPublicationYear "2008" @default.
- W2552593347 type Work @default.
- W2552593347 sameAs 2552593347 @default.
- W2552593347 citedByCount "0" @default.
- W2552593347 crossrefType "journal-article" @default.
- W2552593347 hasAuthorship W2552593347A5003442418 @default.
- W2552593347 hasAuthorship W2552593347A5004302802 @default.
- W2552593347 hasAuthorship W2552593347A5006190727 @default.
- W2552593347 hasAuthorship W2552593347A5015542767 @default.
- W2552593347 hasAuthorship W2552593347A5018176156 @default.
- W2552593347 hasAuthorship W2552593347A5059838967 @default.
- W2552593347 hasAuthorship W2552593347A5076439728 @default.
- W2552593347 hasConcept C126322002 @default.
- W2552593347 hasConcept C126894567 @default.
- W2552593347 hasConcept C141071460 @default.
- W2552593347 hasConcept C2776364478 @default.
- W2552593347 hasConcept C2776689292 @default.
- W2552593347 hasConcept C2776694085 @default.
- W2552593347 hasConcept C2776755627 @default.
- W2552593347 hasConcept C2777063308 @default.
- W2552593347 hasConcept C2777767877 @default.
- W2552593347 hasConcept C2778119113 @default.
- W2552593347 hasConcept C2778684742 @default.
- W2552593347 hasConcept C2779050716 @default.
- W2552593347 hasConcept C2780611847 @default.
- W2552593347 hasConcept C2781413609 @default.
- W2552593347 hasConcept C2911091166 @default.
- W2552593347 hasConcept C71924100 @default.
- W2552593347 hasConcept C74133956 @default.
- W2552593347 hasConcept C89560881 @default.
- W2552593347 hasConcept C90924648 @default.
- W2552593347 hasConceptScore W2552593347C126322002 @default.
- W2552593347 hasConceptScore W2552593347C126894567 @default.
- W2552593347 hasConceptScore W2552593347C141071460 @default.
- W2552593347 hasConceptScore W2552593347C2776364478 @default.
- W2552593347 hasConceptScore W2552593347C2776689292 @default.
- W2552593347 hasConceptScore W2552593347C2776694085 @default.
- W2552593347 hasConceptScore W2552593347C2776755627 @default.
- W2552593347 hasConceptScore W2552593347C2777063308 @default.
- W2552593347 hasConceptScore W2552593347C2777767877 @default.
- W2552593347 hasConceptScore W2552593347C2778119113 @default.
- W2552593347 hasConceptScore W2552593347C2778684742 @default.
- W2552593347 hasConceptScore W2552593347C2779050716 @default.
- W2552593347 hasConceptScore W2552593347C2780611847 @default.
- W2552593347 hasConceptScore W2552593347C2781413609 @default.
- W2552593347 hasConceptScore W2552593347C2911091166 @default.
- W2552593347 hasConceptScore W2552593347C71924100 @default.
- W2552593347 hasConceptScore W2552593347C74133956 @default.
- W2552593347 hasConceptScore W2552593347C89560881 @default.
- W2552593347 hasConceptScore W2552593347C90924648 @default.
- W2552593347 hasLocation W25525933471 @default.
- W2552593347 hasOpenAccess W2552593347 @default.
- W2552593347 hasPrimaryLocation W25525933471 @default.
- W2552593347 hasRelatedWork W1501454461 @default.
- W2552593347 hasRelatedWork W1999913740 @default.
- W2552593347 hasRelatedWork W2274392177 @default.
- W2552593347 hasRelatedWork W2345395215 @default.
- W2552593347 hasRelatedWork W2546313647 @default.
- W2552593347 hasRelatedWork W2556667196 @default.
- W2552593347 hasRelatedWork W2559674469 @default.
- W2552593347 hasRelatedWork W2563175190 @default.
- W2552593347 hasRelatedWork W2565568893 @default.
- W2552593347 hasRelatedWork W2567452199 @default.
- W2552593347 hasRelatedWork W2571962685 @default.
- W2552593347 hasRelatedWork W2572562147 @default.
- W2552593347 hasRelatedWork W2586381253 @default.
- W2552593347 hasRelatedWork W2586471968 @default.
- W2552593347 hasRelatedWork W2972799950 @default.
- W2552593347 hasRelatedWork W2979429674 @default.
- W2552593347 hasRelatedWork W2994135638 @default.
- W2552593347 hasRelatedWork W2999461557 @default.
- W2552593347 hasRelatedWork W3182027595 @default.
- W2552593347 hasRelatedWork W2740029580 @default.
- W2552593347 isParatext "false" @default.
- W2552593347 isRetracted "false" @default.
- W2552593347 magId "2552593347" @default.
- W2552593347 workType "article" @default.